Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
Saved in:
| Title: | Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. |
|---|---|
| Authors: | Robak T; a Copernicus Memorial Hospital , Medical University of Lodz , Lodz , Poland., Huang H; b Sun Yat-sen University Cancer Center , Guangzhou , Guangdong , China., Jin J; c The First Affiliated Hospital of Zhejiang University College of Medicine , Hangzhou , Zhejiang , China., Zhu J; d Beijing Cancer Hospital , Beijing , China., Liu T; e West China Hospital of Sichuan University , Chengdu , Sichuan , China., Samoilova O; f Nizhniy Novgorod Region Clinical Hospital , Nizhniy Novgorod , Russian Federation., Pylypenko H; g Cherkassy Regional Oncology Dispensary , Cherkassy , Ukraine., Verhoef G; h University Hospital Leuven , Leuven , Belgium., Siritanaratkul N; i Siriraj Hospital , Mahidol University , Bangkok , Thailand., Osmanov E; j Cancer Research Center RAMS - N.N. Blokhin Academy of Medical Science , Moscow , Russian Federation., Pereira J; k Hospital das Clinicas da Faculdade de Medicina da USP , São Paolo , Brazil., Mayer J; l Faculty Hospital Brno , Brno , Czech Republic., Hong X; m Fudan University Shanghai Cancer Center , Shanghai , China., Okamoto R; n Department of Chemotherapy , Tokyo Metropolitan Cancer and Infectious Diseases Center , Komagome Hospital , Japan., Pei L; o Janssen Research and Development, LLC , Raritan , NJ , USA., Rooney B; p Janssen Research & Development , High Wycombe , Buckinghamshire , UK., van de Velde H; q Millennium Pharmaceuticals, Inc. , Cambridge , MA , USA , a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Cavalli F; r Oncology Institute of Southern Switzerland, Ospedale San Giovanni , Bellinzona , Ticino , Switzerland. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2019 Jan; Vol. 60 (1), pp. 172-179. Date of Electronic Publication: 2017 Jun 05. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
